Specifications tableSubject areaPharmacologyMore specific subject areaPreclinical drug developmentType of dataFigures and tablesHow data was acquiredAffymetrix Human Genome U133 plus 2.0 arrayData formatRaw (.CEL) and normalizedExperimental factorsHuman skin-derived precursors (hSKP) were differentiated towards hepatic cells (hSKP-HPC) as previously documented [@bib2]. These cells were exposed for 24h to a cocktail of insulin (100 nM), glucose (4,5 mg/mL), sodium oleate (65 μM), palmitic acid (45 μM), tumor necrosis factor alpha (TNF-α) (50 ng/mL), interleukin-1 beta (IL-1β) (25 ng/mL) and transforming growth factor beta 1 (TGF-β1) (8 ng/mL). The obtained *in vitro* model was termed 'hSKP-HPC NASH' and was evaluated in the presence or absence of elafibranor (10 μM or 30 μM). Bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO)-treated samples served as controls.Experimental featuresTotal RNA was extracted from 'hSKP-HPC' control samples (n = 3), 'hSKP-HPC NASH' (n = 3), 'hSKP-HPC NASH' + elafibranor 10 μM (n = 3) and 'hSKP-HPC NASH' + elafibranor 30 μM (n = 3). Analyses were conducted using Robust Multichip Average (RMA) Express, Transcriptome Analysis Console (TAC) (version 4.0.025, Applied Biosystems) and Ingenuity Pathway Analysis (IPA) (version 43605602, Qiagen).Data source locationDepartment of *In Vitro* Toxicology and Dermato-Cosmetology (IVTD), Vrije Universiteit Brussel (VUB), Brussels, Belgium.Data accessibilityRaw data is available at the Gene Expression Omnibus (GEO) from NCBI (GSE126484, [www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126484](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126484){#intref0010}).Related research articleJ. Boeckmans, K. Buyl, A. Natale, V. Vandenbempt, S. Branson, V. De Boe, V. Rogiers, J. De Kock, R.M. Rodrigues, T. Vanhaecke, Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH, Pharmacol. Res., 2019, In Press [@bib1].**Value of the data**•Human-based *in vitro* models can contribute to the pharmacological investigation of NASH and the development of potential anti-NASH drugs [@bib3].•These transcriptomics data of a human skin stem cell-derived in vitro model for NASH, can be used for data mining when investigating NASH *in vitro*. They can also be utilized in comparative transcriptomics studies using other human-based datasets.•This is the first publicly available microarray dataset evaluating elafibranor using stem cell-derived hepatic cells.

1. Data {#sec1}
=======

Whole genome transcriptomics data were obtained from hSKP-HPC exposed to a cocktail of insulin, glucose, fatty acids and inflammatory cytokines, mimicking NASH *in vivo.* In addition, data from NASH-triggered cells concomitantly exposed to elafibranor at two different concentrations is also reported. All data were generated using Affymetrix Human Genome U133 plus 2.0. and processed using Robust Multichip Average (RMA) Express, Transcriptome Analysis Console (TAC) (version 4.0.025, Applied Biosystems) and Ingenuity Pathway Analysis (IPA) (version 43605602, Qiagen). The transcriptomics data that were generated are visualized through a principle Component Analysis (PCA) plot ([Fig. 1](#fig1){ref-type="fig"}a), hierarchical clustering ([Fig. 1](#fig1){ref-type="fig"}b) and volcano plots ([Fig. 2](#fig2){ref-type="fig"}). Top 10 up- and down-regulated genes are listed in [Table 1](#tbl1){ref-type="table"}. A proof of principle of the use of the novel *in vitro* model for anti-NASH drug testing is represented in [Fig. 3](#fig3){ref-type="fig"}.Fig. 1a) PCA plot of 'hSKP-HPC control' (n = 3), 'hSKP-HPC NASH' (n = 3), 'hSKP-HPC NASH + 10 μM elafibranor (n = 3) and 'hSKP-HPC NASH + 30 μM elafibranor (n = 3). b) Hierarchical clustering of 'hSKP-HPC control', 'hSKP-HPC NASH', 'hSKP-HPC NASH' + elafibranor 10 μM and 'hSKP-HPC NASH' + elafibranor 30 μM.Fig. 1Fig. 2Volcano plots representing significantly modulated probesets between a) 'hSKP-HPC NASH' *vs* 'hSKP-HPC' control samples, (b) 'hSKP-HPC NASH' + elafibranor 10 μM *vs* 'hSKP-HPC NASH' and (c) 'hSKP-HPC NASH' + elafibranor 30 μM *vs* 'hSKP-HPC NASH'. \[Analysis cut-off: fold change \[-2; +2\], p \< 0.05 (eBayes ANOVA)\] \[green = down-regulated; red = up-regulated\].Fig. 2Table 1Top-10 highest up- and down-regulated genes between 'hSKP-HPC NASH' *vs* control samples, 'hSKP-HPC NASH' + elafibranor 10 μM *vs* 'hSKP-HPC NASH' and 'hSKP-HPC NASH' + elafibranor 30 μM *vs* 'hSKP-HPC NASH'. \[Analysis cut-off: fold change \[-2; +2\], p ≤ 0.05 (Fischer\'s exact test)\].Table 1'hSKP-HPC NASH' *vs* control samples'hSKP-HPC NASH' + elafibranor 10 μM *vs* 'hSKP-HPC NASH''hSKP-HPC NASH' + elafibranor 30 μM *vs* 'hSKP-HPC NASH'GeneFold changeGeneFold changeGeneFold change![](fx1.gif)\
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2. Experimental design, materials and methods {#sec2}
=============================================

hSKP were differentiated towards hSKP-HPC according to an earlier established 24-day protocol [@bib3]. Subsequently, hSKP-HPC were exposed to insulin (100 nM), glucose (4.5 mg/mL), sodium oleate (65 μM), palmitic acid (45 μM) (all purchased from Sigma-Aldrich), tumor necrosis factor-α (50 ng/mL) (Prospec), interleukin-1β (25 ng/mL) and transforming growth factor-1β (8 ng/mL) (both purchased from Peprotech). Bovine serum albumin (BSA) fatty acid free (Sigma-Aldrich) 7% (w/v) (Sigma-Aldrich) was used to complex sodium oleate in day-24-medium. Palmitic acid and elafibranor (Adooq Bioscience) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Final concentrations of BSA and DMSO in the exposing media were 1.4% (w/v) and 0.15% (v/v), respectively. Exposures were performed for 24h, in the presence or absence of elafibranor (10 μM and 30 μM).

RNA extractions and microarray procedures were performed according to De Kock *et al.* [@bib4]. Three biological replicates of each condition were used. The PCA plot, hierarchical cluster and volcano plots were generated using TAC (RMA-normalized). Pathway analyses were conducted using IPA for which the data were prior normalized using RMA Express. PCA and hierarchical clustering of all analyzed samples are given in [Fig. 1](#fig1){ref-type="fig"}.

Differentially regulated probesets in 'hSKP-HPC NASH' *versus* untriggered hSKP-HPC, which correspond to 3173 differentially expressed genes, are shown in [Fig. 2](#fig2){ref-type="fig"} a--c show the probesets that were significantly modulated in 'hSKP-HPC NASH' treated with elafibranor at 10 μM and 30 μM, respectively corresponding to 107 and 1667 differentially expressed genes.

The 10 highest up-regulated and down-regulated genes in 'hSKP-HPC NASH' *versus* control samples as well as the highest gene expression modulations induced by elafibranor are shown in [Table 1](#tbl1){ref-type="table"}.

To describe the value of the above described data in the elucidation of molecular mechanisms involved in the development or reduction of NASH, the activation of the NFκB pathway, which is a prototypical pro-inflammatory signaling pathway, has been investigated. As shown in [Fig. 3](#fig3){ref-type="fig"}, the NFκB complex is activated in the 'hSKP-HPC NASH' model, but becomes inhibited in the presence of elafibranor (30 μM). Further analysis of this finding as well as interpretation of the reported data in the context of evaluation of anti-NASH properties of elafibranor, can be found in the corresponding research article [@bib1].
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